OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Acquires 125,000 Shares

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) CEO Phillip Md Et Al Frost acquired 125,000 shares of the company's stock in a transaction that occurred on Tuesday, April 8th. The shares were acquired at an average price of $1.48 per share, with a total value of $185,000.00. Following the acquisition, the chief executive officer now owns 213,876,448 shares in the company, valued at $316,537,143.04. This trade represents a 0.06 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Thursday, April 10th, Phillip Md Et Al Frost purchased 125,000 shares of OPKO Health stock. The stock was purchased at an average cost of $1.36 per share, for a total transaction of $170,000.00.
• On Tuesday, April 1st, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was bought at an average price of $1.65 per share, with a total value of $165,000.00.
• On Friday, March 28th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The shares were purchased at an average price of $1.70 per share, for a total transaction of $255,000.00.
• On Monday, March 17th, Phillip Md Et Al Frost acquired 200,000 shares of OPKO Health stock. The stock was acquired at an average price of $1.74 per share, for a total transaction of $348,000.00.
• On Friday, February 28th, Phillip Md Et Al Frost acquired 67,434 shares of OPKO Health stock. The stock was bought at an average cost of $1.71 per share, with a total value of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost bought 47,537 shares of OPKO Health stock. The shares were purchased at an average cost of $1.47 per share, for a total transaction of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost bought 150,000 shares of OPKO Health stock. The stock was bought at an average price of $1.47 per share, for a total transaction of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock. The shares were acquired at an average cost of $1.48 per share, for a total transaction of $740,000.00.

OPKO Health Stock Up 4.0 %

OPKO Health stock traded up $0.06 during mid-day trading on Friday, reaching $1.42. 2,666,302 shares of the company's stock were exchanged, compared to its average volume of 3,950,557. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a twelve month low of $1.15 and a twelve month high of $2.04. The company has a market cap of $950.24 million, a P/E ratio of -7.45 and a beta of 1.78. The company has a fifty day moving average of $1.69 and a 200-day moving average of $1.58.

Remove Ads

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $183.60 million for the quarter, compared to analysts' expectations of $155.42 million. Sell-side analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on OPK. Barrington Research reissued an "outperform" rating and issued a $2.25 price target on shares of OPKO Health in a research note on Wednesday, March 12th. HC Wainwright restated a "buy" rating and set a $3.00 target price on shares of OPKO Health in a report on Monday, April 7th. Finally, StockNews.com raised OPKO Health from a "sell" rating to a "hold" rating in a report on Monday, March 3rd.

Institutional Trading of OPKO Health

Hedge funds have recently added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 11,089 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after buying an additional 12,417 shares in the last quarter. Orion Portfolio Solutions LLC purchased a new stake in OPKO Health during the 3rd quarter worth about $45,000. Cibc World Markets Corp purchased a new position in shares of OPKO Health in the 4th quarter valued at about $45,000. Finally, Zacks Investment Management acquired a new stake in shares of OPKO Health during the 4th quarter worth about $49,000. Institutional investors and hedge funds own 64.63% of the company's stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.